All NewsFDA BriefsOncology IconsSpecial ReportsVoices from the Field
Conference CoverageConference ListingData Dialogue with the Oncology Brothers
All VideosCase-Based Peer PerspectivesExpert Perspective Virtual Tumor BoardInterviewsInvestigator PerspectivesMedical World NewsPivotal Practice Views with the Oncology BrothersPodcastsPrecision Medicine
All PublicationsEvolving ParadigmsPeers & Perspectives in OncologyTargeted Therapies in Oncology
CME/CE
Case-Based Roundtable SeriesClinical TrialsPartnersPrecision Medicine PerspectivesPress ReleasesSponsored ContentTreatment Resources
eNewsletterPrint Subscription
BRAIN CANCER
BREAST CANCERBREAST CANCER
GENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERS
GENOMIC TESTINGGENOMIC TESTING
GI CANCERSGI CANCERSGI CANCERSGI CANCERSGI CANCERS
GYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERS
HEAD & NECK CANCERS
HEMATOLOGYHEMATOLOGY
IMMUNOTHERAPYIMMUNOTHERAPY
LEUKEMIASLEUKEMIASLEUKEMIASLEUKEMIAS
LUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCER
LYMPHOMASLYMPHOMASLYMPHOMASLYMPHOMAS
MPNs
MULTIPLE MYELOMA
NTRK GENE FUSIONS
SARCOMA
SKIN CANCERSSKIN CANCERS
THYROID CANCERS
Spotlight -
  • Biomarker-Driven Lung Cancer
  • GIST
  • HER2-Positive Breast Cancer
  • Chronic Lymphocytic Leukemia
  • Small Cell Lung Cancer
  • Renal Cell Carcinoma
BRAIN CANCER
BREAST CANCERBREAST CANCER
GENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERS
GENOMIC TESTINGGENOMIC TESTING
GI CANCERSGI CANCERSGI CANCERSGI CANCERSGI CANCERS
GYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERS
HEAD & NECK CANCERS
HEMATOLOGYHEMATOLOGY
IMMUNOTHERAPYIMMUNOTHERAPY
LEUKEMIASLEUKEMIASLEUKEMIASLEUKEMIAS
LUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCER
LYMPHOMASLYMPHOMASLYMPHOMASLYMPHOMAS
MPNs
MULTIPLE MYELOMA
NTRK GENE FUSIONS
SARCOMA
SKIN CANCERSSKIN CANCERS
THYROID CANCERS
    • CME/CE
Advertisement

Investigational Therapy in Mantle Cell Lymphoma: KTE-X19 CAR T-Cell Therapy

home / investigator-perspectives / investigational-therapy-in-mantle-cell-lymphoma-kte-x19-car-t-cell-therapy

Michael Wang, MD, reacts to recent data and the potential to treat patients with relapsed or refractory mantle cell lymphoma with KTE-X19, an investigational CAR T-cell therapy.

Advertisement

Risk Stratification of Mantle Cell Lymphoma

EP. 1: Risk Stratification of Mantle Cell Lymphoma

Targeted Oncology
August 24th 2020

Watch


Novel Therapies for Mantle Cell Lymphoma

EP. 2: Novel Therapies for Mantle Cell Lymphoma

Targeted Oncology
August 24th 2020

Watch


KTE-X19 Treatment for R/R Mantle Cell Lymphoma

EP. 3: KTE-X19 Treatment for R/R Mantle Cell Lymphoma

Targeted Oncology
August 24th 2020

Watch


Implications of ZUMA-2 in R/R Mantle Cell Lymphoma

EP. 4: Implications of ZUMA-2 in R/R Mantle Cell Lymphoma

Targeted Oncology
August 24th 2020

Watch


KTE-X19 for R/R MCL: Treatment Considerations

EP. 5: KTE-X19 for R/R MCL: Treatment Considerations

Targeted Oncology
August 24th 2020

Watch


MRD Assessment in Mantle Cell Lymphoma

EP. 6: MRD Assessment in Mantle Cell Lymphoma

Targeted Oncology
August 24th 2020

Watch

Advertisement

Limitations in Treating R/R Mantle Cell Lymphoma

EP. 7: Limitations in Treating R/R Mantle Cell Lymphoma

Targeted Oncology
August 24th 2020

Watch

About Us
Advertise
Contact Us
CureToday.com
CancerNetwork.com
OncLive.com
OncNursingNews.com
Do Not Sell My Information
Privacy
Terms & Conditions
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777

© 2023 MJH Life Sciences

All rights reserved.